S-Cube Presents Three Studies on Nemvastobart at ESMO, Outlines Combination Therapy Expansion Strategy
Predicted impact: Low· Actual: +9.2% vs sector, volume 0.8× normal (5 trading days)
Conference presentations of drug study data; no revenue size disclosed, routine clinical news.